Vedtægter for Novo Nordisk A/S 2024
March 25, 2024 03:51 ET
|
Novo Nordisk A/S
Vedtægter for Novo Nordisk A/S 2024
Vedhæftet fil
Vedtægter 21 Mar 2024
...
Novo Nordisk A/S - Articles of Association 2024
March 25, 2024 03:51 ET
|
Novo Nordisk A/S
Novo Nordisk's Articles of Association 2024
Attachment
Articles of Association 21 Mar 2024
...
Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
March 21, 2024 11:55 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending...
Resolutions from the Annual General Meeting of Novo Nordisk A/S
March 21, 2024 10:59 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “We are very...
Novo Nordisk A/S - share repurchase programme
March 18, 2024 10:18 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk A/S - share repurchase programme
March 11, 2024 08:46 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 11 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
March 08, 2024 13:42 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application...
Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
March 07, 2024 02:00 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025. The day will be centred...
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
March 05, 2024 04:53 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to...
Novo Nordisk A/S - share repurchase programme
March 04, 2024 09:29 ET
|
Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 04 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No...